Recently added
This page was added on 08 February 2023.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
Merck Sharp & Dohme (Australia)
Administration route
Intramuscular injection
Vaccine group
Pneumococcal conjugate vaccines
Description:
Registered for use in people aged ≥6 weeks
15vPCV - 15-valent pneumococcal conjugate vaccine
Each 0.5 mL dose of vaccine contains:
- 2.0 µg each of pneumococcal purified capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F
- 4.0 µg of pneumococcal purified capsular polysaccharide serotype 6B
- Histidine
- Polysorbate 20
Antigens are conjugated to 30 µg of non-toxic diphtheria CRM197 protein, adsorbed on 125 µg of aluminium (as aluminium phosphate adjuvant).
For Product Information and Consumer Medicine Information about Vaxneuvance visit the Therapeutics Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Page history
Last updated
Last reviewed
Related diseases